Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

Inclusion criteria

• Male/female participants who are 18 years of age or older on the day of signing informed consent with histologically or cytologically confirmed diagnosis of invasive breast cancer will be enrolled in this study.
• Participants have been confirmed to be ER negative, HER2 negative according to the latest ASCO/CAP criteria. However, it does not matter whether the result is positive or negative for PgR.
• Participants have been confirmed to be PD-L1 positive in each site's evaluation using biopsy specimen or surgical specimen.
• Participants who have received not more than 1 prior chemotherapy regimen (including those with no prior chemotherapy) for recurrent breast cancer, excluding trial drugs of this clinical trial. (Participants with prior paclitaxel or bevacizumab for recurrent breast cancer are excluded.) However, prior treatment with Olaparib for metastatic recurrence or unresectable advanced cancer in participants with BRCA gene pathogenic variant is allowed (not counted as 1 regimen).
• Participants must have recurred after treatment with an anti-PD-1/PD-L1 antibody administered as monotherapy or in combination with other ICIs or chemotherapies as a perioperative drug therapy for triple negative breast cancer.
• Have an Eastern Cooperative Oncology Group performance status of 0 to 1.

Exclusion criteria

• Participants with progressive disease on RECIST or clinically diagnosed during preoperative ICI and chemotherapy.
• Known additional malignancy that is progressing or has required active treatment within the past 3 years prior to enrollment.
• Has known active CNS metastases and/or carcinomatous meningitis.
• Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.